A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas

A Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Gliomas
This study is currently recruiting participants.
Verified July 2011 by Clinical Research Center for Solid Tumor, Korea

First Received on June 13, 2009.  
Last Updated on July 25, 2011  
History of Changes
Sponsor: Clinical Research Center for Solid Tumor, Korea
Collaborator: Seoul National University Hospital
Information provided by: Clinical Research Center for Solid Tumor, Korea
ClinicalTrials.gov Identifier: NCT00921167

To assess the efficacy and safety of bevacizumab plus irinotecan for the patients with recurrent anaplastic astrocytoma or with recurrent glioblastoma multiforme

Condition Intervention Phase
Drug: Bevacizumab/Irinotecan Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study to Evaluate the Efficacy of Bevacizumab Plus Irinotecan in Recurrent Anaplastic Astrocytoma or Recurrent Glioblastoma Multiforme

Resource links provided by NLM:

Further study details as provided by Clinical Research Center for Solid Tumor, Korea:

Primary Outcome Measures:

  • Progression-free survival [ Time Frame: 6 months, 1 year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

  • Objective response rate [ Time Frame: 6 weeks, 12 weeks ] [ Designated as safety issue: No ]
  • Overall survival [ Time Frame: 6 months, 1 year ] [ Designated as safety issue: No ]
  • Disease-control rate [ Time Frame: 6 weeks, 12 weeks ] [ Designated as safety issue: No ]
  • Adverse event [ Time Frame: 3 weeks, 6 weeks, 9 weeks, 12 weeks ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 32
Study Start Date: June 2009
Estimated Study Completion Date: June 2012
Estimated Primary Completion Date: June 2012 (Final data collection date for primary outcome measure)


Assigned Interventions
Experimental: Bevacizumab/Irinotecan Drug: Bevacizumab/Irinotecan

Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically diagnosed recurrent anaplastic astrocytoma or recurrent glioblastoma multiforme
  • At least 18 years of age
  • Performance status of 0 and 1 on the Eastern Cooperative Oncology Group (ECOG) criteria
  • One or more measurable disease
  • Adequate hematologic (neutrophil count >= 1500/uL, platelets >= 100,000/uL), hepatic (transaminase =< upper normal limit (UNL)x2.5, bilirubin level =< UNLx1.5, alkaline phosphatase =< UNLx2.5), and renal (creatinine clearance >= 30mL/min)
  • Expected life time more than at least 2 months
  • A patients who signed the informed consent prior to the participation in the study

Exclusion Criteria:

  • A pregnant or lactating patient
  • A patient of childbearing potential without being tested for pregnancy at baseline or with a positive test. (A premenopausal woman with the amenorrhea period of at least 12 months or longer is considered to have non-childbearing potential.)
  • A man or woman of childbearing potential without the willingness to use a contraceptive measures during the study
  • A patient with history of another malignant disease within past 3 years, except curatively treated basal cell carcinoma of the skin, cervical carcinoma in situ, and early gastric cancer
  • Medically uncontrolled serious heart, lung, neurological, psychological, or metabolic disease
  • Uncontrolled serious infection
  • Enrollment in other study within 30 days
  • Hemorrhage on baseline radiologic examination
  • A patient who refused to sign the informed consent
  Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00921167

Contact: Se-Hoon Lee, MD +82-2-2072-0832 shlee119@snu.ac.kr

Korea, Republic of
Seoul National University Hospital Recruiting
Seoul, Korea, Republic of
Contact: Se-Hoon Lee, MD     +82-2-2072-0832     shlee119@snu.ac.kr    
Sponsors and Collaborators
Clinical Research Center for Solid Tumor, Korea
Seoul National University Hospital
  More Information

No publications provided

Responsible Party: Dae Seog Heo/Professor, Seoul National University Hospital
ClinicalTrials.gov Identifier: NCT00921167    
History of Changes
Other Study ID Numbers: CRCST-L-0006
Study First Received: June 13, 2009
Last Updated: July 25, 2011
Health Authority: South Korea: Institutional Review Board

Keywords provided by Clinical Research Center for Solid Tumor, Korea:


Additional relevant MeSH terms:

Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Radiation-Sensitizing Agents
Physiological Effects of Drugs
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Growth Inhibitors

ClinicalTrials.gov processed this record on August 21, 2012

Leave a Reply

You can use these HTML tags

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>




seven + one =